18F-FDG uptake at initial staging of the adrenocortical cancers: A diagnostic tool but not of prognostic value

World Journal of Surgery

Volumn 37, Issue 1, 2013, Pages 107-112

  Tessonnier, L ^a   Ansquer, C ^b   Bournaud, C ^c   Sebag, F ^a   Mirallie E ^b   Lifante, J C ^c   Palazzo, F F ^a   Morange, I ^a   Drui, D ^b   De La Foucardere C ^d   Mancini, J ^a,e   Taieb D ^a  

^a TIMONE HOSPITAL   (France)

^b NANTES UNIVERSITY HOSPITAL   (France)

^c Civil Hospices of Lyon ^*  (France)

^d CENTRE LÉON BÉRARD   (France)

^e AIX MARSEILLE UNIVERSITY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

DIAGNOSTIC AGENT; FLUORODEOXYGLUCOSE F 18; RADIOPHARMACEUTICAL AGENT;

ADRENAL CORTEX TUMOR; ADULT; AGED; ARTICLE; CANCER STAGING; FEMALE; HUMAN; MALE; MIDDLE AGED; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; RETROSPECTIVE STUDY; SCINTISCANNING; VERY ELDERLY;

ADRENAL CORTEX NEOPLASMS; ADULT; AGED; AGED, 80 AND OVER; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; RADIOPHARMACEUTICALS; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84871750254     PISSN: 03642313     EISSN: 14322323     Source Type: Journal    
DOI: 10.1007/s00268-012-1802-y     Document Type: Article

References (21)

1. Fassnacht M, Libe R, Kroiss M et al (2011) Adrenocortical carcinoma: a clinician's update. Nat Rev Endocrinol 7:323-335
2. Kreissig R, Amthauer H, Krude H et al (2000) The use of FDG-PET and CT for the staging of adrenocortical carcinoma in children. Pediatr Radiol 30:306
3. Minn H, Salonen A, Friberg J et al (2004) Imaging of adrenal incidentalomas with PET using (11)C-metomidate and (18)F-FDG. J Nucl Med 45:972-979
4. Zettinig G, Mitterhauser M, Wadsak W et al (2004) Positron emission tomography imaging of adrenal masses: (18)F-fluorodeoxyglucose and the 11beta-hydroxylase tracer (11)C-metomidate. Eur J Nucl Med Mol Imaging 31:1224-1230
5. Mackie GC, Shulkin BL, Ribeiro RC et al (2006) Use of [18F]fluorodeoxyglucose positron emission tomography in evaluating locally recurrent and metastatic adrenocortical carcinoma. J Clin Endocrinol Metab 91:2665-2671
6. 18F-FDG PET/CT add diagnostic accuracy in incidentally identified non-secreting adrenal tumours? Eur J Nucl Med Mol Imaging 35:2018-2025
7. 18F- fluorodeoxyglucose positron emission tomography for the diagnosis of adrenocortical tumors: a prospective study in 77 operated patients. J Clin Endocrinol Metab 94:1713-1722
8. 18F-FDG PET for the identification of adrenocortical carcinomas among indeterminate adrenal tumors at computed tomography scanning. World J Surg 34:1506-1510
9. 18F-FDG PET/CT in the characterization and surgical decision concerning adrenal masses: a prospective multicentre evaluation. Eur J Nucl Med Mol Imaging 37:1669-1678
10. Boland GW, Dwamena BA, Sangwaiya MJ et al (2011) Characterization of adrenal masses by using FDG PET: a systematic review and meta-analysis of diagnostic test performance. Radiology 259:117-126
11. Leboulleux S, Dromain C, Bonniaud G et al (2006) Diagnostic and prognostic value of 18-fluorodeoxyglucose positron emission tomography in adrenocortical carcinoma: a prospective comparison with computed tomography. J Clin Endocrinol Metab 91:920-925
12. Fenske W, Volker HU, Adam P et al (2009) Glucose transporter GLUT1 expression is an stage-independent predictor of clinical outcome in adrenocortical carcinoma. Endocr Relat Cancer 16:919-928
13. Fassnacht M, Johanssen S, Quinkler M et al (2009) Limited prognostic value of the 2004 International Union Against Cancer staging classification for adrenocortical carcinoma: proposal for a revised TNM classification. Cancer 115:243-250
14. Deandreis D, Leboulleux S, Caramella C et al (2011) FDG PET in the management of patients with adrenal masses and adrenocortical carcinoma. Horm Cancer 2:354-362
15. Gallamini A, Hutchings M, Rigacci L et al (2007) Early interim 2-[18F]fluoro-2-deoxy-d-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study. J Clin Oncol 25:3746-3752
16. Haioun C, Itti E, Rahmouni A et al (2005) [18F]fluoro-2-deoxy-d-glucose positron emission tomography (FDG-PET) in aggressive lymphoma: an early prognostic tool for predicting patient outcome. Blood 106:1376-1381
17. Paesmans M, Berghmans T, Dusart M et al (2010) Primary tumor standardized uptake value measured on fluorodeoxyglucose positron emission tomography is of prognostic value for survival in non-small cell lung cancer: update of a systematic review and meta-analysis by the European Lung Cancer Working Party for the International Association for the Study of Lung Cancer Staging Project. J Thorac Oncol 5:612-619
18. 18F-FDG PET in patients with head and neck squamous cell cancer. AJR Am J Roentgenol Rad Ther Nucl Med 192:W156-W160
19. Kidd EA, Siegel BA, Dehdashti F et al (2007) The standardized uptake value for F-18 fluorodeoxyglucose is a sensitive predictive biomarker for cervical cancer treatment response and survival. Cancer 110:1738-1744
20. Kato H, Nakajima M, Sohda M et al (2009) The clinical application of (18)F-fluorodeoxyglucose positron emission tomography to predict survival in patients with operable esophageal cancer. Cancer 115:3196-3203
21. Vander Heiden MG, Cantley LC, Thompson CB (2009) Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 324:1029-1033